Cardiology meeting set to reveal competitive landscape for heart therapies

At the European Society of Cardiology's annual meeting this week, multiple drugmakers including AstraZeneca, Ionis, Cytokinetics, Novartis, and CRISPR Therapeutics are scheduled to present clinical data. The results will likely clarify the commercial prospects for their cardiovascular programs. Investors and clinicians will be watching closely for signals on efficacy and safety that could shift market positioning.